The drug, Kymriah, is the first CAR-T therapy to come before the FDA and was approved for the treatment of patients up to 25 years old with relapsed acute lymphoblastic leukemia.
A clinical trial of the leukemia drug deemed a “breakthrough” by physicians revealed 83 percent of patients treated with CAR-T cell therapy have gone into remission.
While the price tag of $475,000 per treatment seems staggering, it is much less than the $649,000 per treatment price analysts expected.
“We’re entering a new frontier in medical innovation with the ability to reprogram a patient’s own cells to attack a deadly cancer,” said FDA Commissioner Scott Gottlieb, MD.
The FDA’s approval came weeks earlier than expected.
More articles on supply chain:
US Bioservices to pay $13.4M to resolve kickback suit
Samsung widens stake in prescription drug market through partnership with Japanese pharmaceutical company
Patients brace for price of ‘breakthrough’ leukemia drug CTL019
